{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:15:02Z","timestamp":1780614902864,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05700-7","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:07:26Z","timestamp":1747667246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationship between urinary pH and efficacy of Bacillus Calmette-Gu\u00e9rin treatment in patients with carcinoma in situ of the bladder"],"prefix":"10.1007","volume":"43","author":[{"given":"Ryo","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Notsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Shinsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Niwakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"5700_CR1","unstructured":"EAU guidelines on non-muscle-invasive bladder cancer (2025). https:\/\/uroweb.org\/guidelines."},{"key":"5700_CR2","doi-asserted-by":"publisher","first-page":"CD012112","DOI":"10.1002\/14651858.CD012112.pub2","volume":"3","author":"ARH Shepherd","year":"2017","unstructured":"Shepherd ARH et al (2017) Intravesical BCG with interferon-alpha versus intravesical BCG for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev. 3:CD012112. https:\/\/doi.org\/10.1002\/14651858.CD012112.pub2","journal-title":"Cochrane Database Syst Rev."},{"key":"5700_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"E Solsona","year":"2015","unstructured":"Solsona E et al (2015) Sequential combination of mitomycin C plus bacillus Calmette-Gu\u00e9rin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol. 67:508\u2013516. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.026","journal-title":"Eur Urol."},{"key":"5700_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/carcin\/bgr048","volume":"32","author":"J Alguacil","year":"2011","unstructured":"Alguacil J et al (2011) Urinary pH, cigarette smoking and bladder cancer risk. Carcinogenesis 32:843\u2013847. https:\/\/doi.org\/10.1093\/carcin\/bgr048","journal-title":"Carcinogenesis"},{"key":"5700_CR5","first-page":"9407","volume":"25","author":"BV Stone","year":"2018","unstructured":"Stone BV et al (2018) Urinary pH and the risk of recurrence in patients with non-muscle invasive bladder cancer. Can J Urol 25:9407\u20139412","journal-title":"Can J Urol"},{"key":"5700_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han J et al (2020) Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother 129:110393. https:\/\/doi.org\/10.1016\/j.biopha.2020.110393","journal-title":"Biomed Pharmacother"},{"key":"5700_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","volume":"17","author":"JH van Puffelen","year":"2020","unstructured":"van Puffelen JH et al (2020) Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol 17:513\u2013525. https:\/\/doi.org\/10.1038\/s41585-020-0346-4","journal-title":"Nat Rev Urol"},{"key":"5700_CR8","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto A et al (2012) Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 72:2746\u20132756. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1272","journal-title":"Cancer Res"},{"key":"5700_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas S et al (2016) Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res 76:1381\u20131390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1743","journal-title":"Cancer Res"},{"key":"5700_CR10","unstructured":"WHO classification of tumors (2022). Urinary and male genital tumours, 5th edition. IARC. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Urinary-And-Male-Genital-Tumours-2022."},{"key":"5700_CR11","doi-asserted-by":"publisher","first-page":"239.e1","DOI":"10.1016\/j.urolonc.2018.01.018","volume":"36","author":"D D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea D et al (2018) Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool. Urol Oncol 36:239.e1\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2018.01.018","journal-title":"Urol Oncol"},{"key":"5700_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J et al (2012) Female Gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1 Patients with G3 bladder cancer treated with BCG. Eur Urol 62:118\u2013125","journal-title":"Eur Urol"},{"key":"5700_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031. (Discussion 475)","journal-title":"Eur Urol"},{"key":"5700_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"5700_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2174\/138920312804871094","volume":"13","author":"I Konieczna","year":"2012","unstructured":"Konieczna I et al (2012) Bacterial urease and its role in long-lasting human diseases. Curr Protein Pept Sci 13:789\u2013806. https:\/\/doi.org\/10.2174\/138920312804871094","journal-title":"Curr Protein Pept Sci"},{"key":"5700_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/s1286-4579(00)00312-9","volume":"2","author":"RA Burne","year":"2000","unstructured":"Burne RA, Chen YY (2000) Bacterial ureases in infectious diseases. Microbes Infect 2:533\u2013542. https:\/\/doi.org\/10.1016\/s1286-4579(00)00312-9","journal-title":"Microbes Infect"},{"key":"5700_CR17","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1128\/IAI.72.7.4200-4209.2004","volume":"72","author":"K Sendide","year":"2004","unstructured":"Sendide K et al (2004) Mycobacterium bovis BCG urease attenuates major histocompatibility complex class II trafficking to the macrophage cell surface. Infect Immun 72:4200\u20134209. https:\/\/doi.org\/10.1128\/IAI.72.7.4200-4209.2004","journal-title":"Infect Immun"},{"key":"5700_CR18","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","volume":"15","author":"H Choi","year":"2024","unstructured":"Choi H et al (2024) Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy. Nat Commun 15:9934. https:\/\/doi.org\/10.1038\/s41467-024-54293-z","journal-title":"Nat Commun"},{"key":"5700_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bju.15571","volume":"129","author":"Y Miyata","year":"2022","unstructured":"Miyata Y et al (2022) Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial. BJU Int 129:534\u2013541. https:\/\/doi.org\/10.1111\/bju.15571","journal-title":"BJU Int"},{"key":"5700_CR20","doi-asserted-by":"publisher","first-page":"291.e1","DOI":"10.1016\/j.urolonc.2024.04.011","volume":"42","author":"J Knorr","year":"2024","unstructured":"Knorr J et al (2024) An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancer. Urol Oncol 42:291.e1-291.e11. https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.011","journal-title":"Urol Oncol"},{"key":"5700_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/iju.14139","volume":"27","author":"H Herr","year":"2020","unstructured":"Herr H (2020) Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Gu\u00e9rin? Int J Urol 27:72\u201374. https:\/\/doi.org\/10.1111\/iju.14139","journal-title":"Int J Urol"},{"key":"5700_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns RA et al (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85\u201395. https:\/\/doi.org\/10.1038\/nrc2981","journal-title":"Nat Rev Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05700-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:50:49Z","timestamp":1767966649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05700-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5700"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05700-7","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This single-center study was approved by the Institutional Review Board of Shizuoka Cancer Center (J2024-218-2024-1-3).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional reviewer board"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study. The study information was displayed on the hospital\u2019s homepage to provide a means of opting out. Registry and the registration no. of the study: 4766.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"317"}}